KUALA LUMPUR, Sept 21 – Hovid Bhd, a Malaysian-based pharmaceutical company producing more than 400 products, recently announced that its Chemor manufacturing facility has been awarded the Therapeutic Goods Administration Good Manufacturing Practices (TGA-GMP) certification.
Receipt of this certification is an essential requirement for the export of Hovid’s therapeutic goods into countries such as Australia and New Zealand. It also verifies that Hovid’s manufacturing processes have been developed to produce quality products that meet international standards.
TGA-GMP is an international recognised certification by the Australia’s regulatory authority for therapeutic goods such as medicines, medical devices, and diagnostic tests, granted only to companies whose manufacturing procedures and facilities demonstrate a high degree of consistency, safety, and quality.
The certification enables Hovid to pursue international distribution opportunities, especially in Australia and New Zealand, as well as in other global markets that accepts TGA-GMP certification fort market access. Hovid is one of the very few pharmaceutical companies in Malaysia to be granted the TGA-GMP.
“At Hovid, we are committed to providing patients worldwide with high quality products backed by our dedicated R&D facilities,” said Hovid Bhd managing director David Ho.
“By obtaining TGA-GMP certification, we can now embark upon our strategy and ambitious for expansion into more key international markets, aiming for rapid global growth and getting more Malaysian made products available globally.”
As the largest pharma exporter in Malaysia with a global sales and distribution network, Hovid will continue to aim for product excellence especially in quality. It will continuously innovate to improve manufacturing lines and R&D-based products that can penetrate market segments worldwide.
